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Multiple system atrophy (MSA) is a progressive neurodegenerative disease characterized by the accumulation of
α-synuclein protein in the cytoplasm of oligodendrocytes, the myelin-producing support cells of the central nervous
system (CNS). The brain is the most lipid-rich organ in the body and disordered metabolism of various lipid constituents
is increasingly recognized as an important factor in the pathogenesis of several neurodegenerative diseases. α-Synuclein
is a 17 kDa protein with a close association to lipid membranes and biosynthetic processes in the CNS, yet its precise
function is a matter of speculation, particularly in oligodendrocytes. α-Synuclein aggregation in neurons is a
well-characterized feature of Parkinson’s disease and dementia with Lewy bodies. Epidemiological evidence
and in vitro studies of α-synuclein molecular dynamics suggest that disordered lipid homeostasis may play a
role in the pathogenesis of α-synuclein aggregation. However, MSA is distinct from other α-synucleinopathies
in a number of respects, not least the disparate cellular focus of α-synuclein pathology. The recent identification of
causal mutations and polymorphisms in COQ2, a gene encoding a biosynthetic enzyme for the production of the
lipid-soluble electron carrier coenzyme Q10 (ubiquinone), puts membrane transporters as central to MSA pathogenesis,
although how such transporters are involved in the early myelin degeneration observed in MSA remains unclear. The
purpose of this review is to bring together available evidence to explore the potential role of membrane transporters
and lipid dyshomeostasis in the pathogenesis of α-synuclein aggregation in MSA. We hypothesize that dysregulation of
the specialized lipid metabolism involved in myelin synthesis and maintenance by oligodendrocytes underlies the
unique neuropathology of MSA.
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Multiple system atrophy (MSA) is a progressive neurode-
generative disease characterized by the clinical triad of
parkinsonism, cerebellar ataxia and autonomic failure. The
distribution of pathology classically encompasses three
functional systems in the central nervous system (CNS);
the striatonigral system, olivopontocerebellar system and
autonomic nuclei of the brainstem and spinal cord [1,2].
MSA typically affects individuals in the sixth decade of life
or later [3] with a mean survival of approximately 9 years
[4,5]. The annual incidence in the age group 50–99 years
has been estimated at 3 cases per 100,000 person years
[6,7]. While the general consensus is that MSA is a highly
sporadic disease, emerging evidence has suggested rare* Correspondence: w.kim@unsw.edu.au
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stated.genetic variants increase susceptibility, although this
appears to be dependent on the geographical distribution
of sample patients [8-11]. Furthermore, albeit scant,
evidence suggesting environmental risk factors similarly
increasing susceptibility has also been reported [12-16].
The pathological hallmark of MSA is the appearance of
glial cytoplasmic inclusions (GCIs) in oligodendrocytes
(Figure 1), the myelin producing support cells of the
central nervous system (CNS). GCIs comprise insoluble
proteinaceous filaments composed chiefly of α-synuclein
(α-syn) [17]. α-Syn is a 17-kDa protein encoded by the
SNCA gene at the cytogenetic location 4q22.1. It is
predominantly expressed in neurons where it appears
to localize in the synaptic terminal and play a role in
vesicle transport and turnover [18-20]. Deposits of
insoluble α-syn also occur in neurons in Parkinson’s
disease (PD) and dementia with Lewy bodies (DLB),
although the filament size and morphology in theseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 A putative model of oligodendrocyte dysfunction in multiple system atrophy. (A) Normal oligodendrocytes with myelin covering the
axon of a neuron. (B) Formation of glial cytoplasmic inclusions (GCIs), composed of aggregated α-synuclein, and demyelination. (C) Demyelination is
followed by neurodegeneration and cell death.
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causes of α-syn aggregation and the reason for the unique
oligodendrocyte focus of pathology in MSA remain
poorly understood. However, in line with advances in
understanding of other neurodegenerative proteinopathies,
including Alzheimer’s disease [22,23], the metabolism of
lipids in the brain is emerging as an important focus in the
study of proteinopathies and α-syn pathophysiology.
For α-syn, such lines of evidence stem from studies which
demonstrate that α-syn readily binds to lipid droplets and
phospholipid bilayers in vitro, whereby lipid membrane
association induces folding of the protein from its
unfolded cytosolic state to a stable α-helical conformation
[19]. In vivo, membrane association and diverse effects on
lipid metabolism appear to be important components of
the physiological function of α-syn in the CNS. It follows
that disruption of lipid metabolism and lipid-membrane
composition and integrity could play an important role in
the pathogenesis of α-synucleinopathies. However, the
specific role of oligodendrocyte membrane transport and
lipid metabolism in MSA remains to be clearly elucidated.
The purpose of this review is to explore the significance
of brain lipid metabolism in MSA pathogenesis. We will
firstly discuss oligodendrocyte-specific processes, specifically
myelin formation, which may underlie the unique glial
focus of MSA pathology. The relevance of lipid membranes
and metabolism to the normal physiology and dysfunction
of α-syn will then be explored. Finally, epidemiological
evidence linking membrane transport and lipid dyshomeos-
tasis to MSA will be discussed.
Review
Oligodendrocyte-specific pathology
In an effort to distinguish processes specific to MSA patho-
genesis, the physiology and maintenance of myelin pre-
sents a natural focus, given the primary lesion in MSA
occurs within oligodendrocytes. Myelin in cross section is
a spiral structure constituted by multiple layers of a spe-
cialized extension of the oligodendrocyte plasma mem-
brane that wraps around axons (reviewed in [24]). Thecomposition of myelin is characterized by high proportions
of cholesterol and glycosphingolipids, which are arranged
in a highly ordered structure with associated structural and
signaling proteins. Hence, this highlights the importance in
maintaining appropriate lipid concentrations, as they are
crucial for the proper formation of myelin.
Myelin is traditionally known to function as an electrical
insulator for axons to facilitate the rapid propagation of
action potentials. However, Ravera and colleagues [25]
have recently demonstrated that similar to mitochondria,
isolated myelin vesicles possess the capacity to undergo
oxidative phosphorylation to generate ATP for axons.
Hence, myelin may hold additional roles that contribute
towards axonal survivability. Therefore, defects in myelin
arising from lipid dyshomeostasis could potentially
perturb the survivability of axons to in turn cause
neurodegeneration as a contributor towards MSA patho-
genesis. The mechanism by which axonal degeneration
induces neurodegeneration is discussed in a review by
Wang et al. [26], although another recent study reported
an absence of axonal degeneration following chronic
dysmyelination in the Long-Evans shaker rat [27].
These rats are characterized by myelination abnormalities
resulting from a mutation in the gene that encodes myelin
basic protein [27]. While such conflicting findings are
possibly the result of varying experimental conditions,
clarification of the relationship between myelin loss, axonal
degeneration and neurodegeneration is required.
Despite the conflicting findings on the link between
myelin integrity, axonal survivability and neurodegeneration,
the disruption of myelin has been proposed to be an early
process in the pathogenesis of MSA by Song and colleagues
[28]. More specifically, the authors observed abnormal
subcellular relocalization of myelin-associated proteins,
which appeared to precede α-syn aggregation into GCIs.
The earliest changes observed included the relocalization
of p25α from the myelin sheath to the cell body of
oligodendrocytes, which was presumed to induce abnormal
expansion of the cell body. Moreover, similar relocalization
patterns were observed with myelin basic protein whilst
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tion in the expanded soma of affected oligodendrocytes. A
previous study of myelin changes in MSA also noted that
proteolysis of myelin basic protein was an early
marker of oligodendrocyte pathology in affected brain
areas and sometimes preceded the appearance of GCIs [29].
Substantiating the relevance of these observations to later
α-syn aggregation in MSA, p25α co-localizes with α-syn in
GCIs and is a potent inducer of α-syn aggregation
in vitro [30-32]. Thus a disruption of myelin synthesis
and maintenance in oligodendrocytes could represent
the primary disturbance in MSA. A possible source of this
disturbance could lie in the synthesis and handling of
key myelin lipids by oligodendrocytes. The consequent
alteration in myelin membrane composition would
then be likely to impact upon membrane association
with α-syn as a precedent to α-syn aggregation. In
addition, with its putative role in diverse lipid biosyn-
thetic pathways, α-syn expression may be governed by
feedback mechanisms operating in response to myelin
lipid abnormalities.
α-Synuclein pathology
α-Synuclein oligomers are key cytotoxic species in
α-synucleinopathies
The α-syn protein contains a highly hydrophobic 12–amino
acid domain at its center (71-VTGVTAVAQKTV-82), which
appears to be essential for fibrilization of the protein [33].
Deletion or disruption of this domain through the addition
of a charged amino acid abrogates the ability of α-syn to
form amyloid fibrils [33]. Insoluble aggregates of α-syn with
this 12 amino acid stretch at their core [33] are the
pathological hallmarks of PD/DLB and MSA in neurons
and oligodendrocytes respectively. However, a significant
body of evidence suggests that mature α-syn fibrils are not
required for cytotoxicity in these disease processes. Instead,
early misfolded forms of α-syn, possibly dimers or small
oligomers, are proposed to be the primary toxic species
[34]. Consistent with this hypothesis, investigations of
α-syn mutants linked to familial forms of PD (A30P and
A53T) have found that both forms undergo self-association
to form soluble oligomers more rapidly than wild-type
protein, however only A53T demonstrates faster formation
of fibrils [35,36]. Underlying their toxicity, α-syn oligomers
assume annular pore-forming configurations which may
be capable of causing inappropriate permeabilization
of cellular membranes [37]. Subsequent aggregation into
visible fibrils may even serve as protective sequestration of
this toxic species [34,38].
Formation of α-synuclein oligomers at the lipid membrane
surface
As highlighted above, under normal conditions α-syn
exists as randomly structured and natively unfoldedmonomer within the cytoplasm. However, at the membrane
surface in the presence of lipids α-syn adopts a dramatic
change in structure to a folded α-helical secondary
structure [39]. A number of studies have suggested
that the helix-rich membrane bound form of α-syn plays a
crucial role in initiating the pathological aggregation of
the protein. Accelerated α-syn aggregation has been
observed as a result of α-syn exposure to long chain
polyunsaturated fatty acids [40] and with increased
binding to membranes and lipid droplets within cells
[41]. In a study of isolated brain fractionates of α-syn,
Lee and colleagues [42] observed progressive aggre-
gation of the protein in the membrane fraction but
no aggregation in the cytosolic fraction after 3 days.
Moreover, addition of cytosolic α-syn to the mem-
brane fraction accelerated aggregation, suggesting
that initial self-association at the membrane may
seed accumulation of the more abundant cytosolic
form of α-syn.Lipid membrane composition influences α-synuclein
association
Additional studies of lipid membrane composition and
structure shed further light on the mechanics of α-syn
membrane association and dysfunction. Fortin and
colleagues [18] observed that α-syn binds preferentially to
lipid raft microdomains in biological membranes. Lipid
raft microdomains have been shown to be essential for
oligodendrocyte survival signaling by providing a favorable
environment for growth factor-mediated integrin activation
[43]. Lipid rafts are highly dynamic sterol- and sphingolipid-
enriched structures, which compartmentalize many cellular
processes occurring in biological membranes [44,45].
Quantitative manipulation of constituent lipid species
leads to disorganization of lipid raft microdomains
and dissociation of proteins bound to the lipid rafts
[46,47]. Fortin and colleagues [18] noted that cholesterol
extraction disrupted lipid rafts and dramatically reduced
α-syn association in vitro. Conversely, Cole and colleagues
[41] loaded HeLa cells expressing wild-type α-syn with
free fatty acid and found significant increases in α-syn
association with membranes and triglyceride-rich lipid
droplets. Thus it appears that the dynamics of intracellular
α-syn association are highly responsive to manipulation of
lipid homeostasis and membrane composition. A
number of studies have shown that the A30P α-syn
mutant associated with familial PD displays defective
binding to lipid membranes, while the A53T mutant
shows no such difference compared to wild-type protein
[18,48,49]. Although there are no known causative α-syn
mutations in MSA, variants of the SNCA gene have
been identified to be associated with an increased risk
for MSA [11,50].
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synaptic vesicle function
α-Syn is expressed primarily by neurons, where it is
especially enriched at their presynaptic terminals
[18,51,52]. α-Syn is described as a natively unfolded
protein since it forms a disordered ‘random coil’
configuration in its cytosolic state [53]. The association of
α-syn with lipid membranes is well established by
in vitro methods [19,39]. Lipid association, moreover,
induces folding of the protein to a stable α-helical
conformation [19,39,54]. However, the significance of
these observations for the physiological function of
the protein in vivo remains incompletely understood.
A study of α-syn structure found high homology of
sequences at the C and N terminals to characteristic
motifs of the fatty acid binding protein (FABP) family,
suggesting α-syn may play a role in intracellular fatty acid
transport [55]. However, subsequent findings have
suggested a more nuanced relationship to lipid membranes
and cellular lipid metabolism. The propensity of α-syn to
bind and stabilize small lipid vesicles [19,41] and the
subcellular localization of the protein at the presynaptic
terminal in neurons [18,51,52] are suggestive of a role in
synaptic transmission. Indeed, transgenic mice lacking
α-syn (α-syn−/−) show deficits in nigrostriatal dopaminergic
neurotransmission [20,56]. On a sub-cellular level, Cabin
and colleagues [56] found that α-syn−/− mice have a 50%
reduction in size of undocked synaptic vesicle pool and
synaptic vesicle depletion after high-frequency stimulation.
The mechanism of this influence on vesicle function
and turnover may rely on the interaction of α-syn with
phospholipase enzymes and associated lipid-mediated
signal transduction. α-Syn binds to and inhibits the
activity of phospholipase D (PLD) [57,58] – an enzyme
involved in lipid-mediated signaling cascades responsible for
regulating functions including cytoskeletal rearrangement
and endocytosis [59]. PLD inhibition appears to be required
for synaptic vesicle fusion with the target membrane and
may regulate synaptic vesicle recycling. This is consistent
with the results of Cabin and colleagues [56] who showed a
reduction in the synaptic vesicle pool in α-syn−/− mice. A
further role in intracellular signaling was suggested by
Narayanan and colleagues [60], who found that α-syn also
binds to phospholipase Cβ (PLCβ), which is a G-protein
coupled enzyme in the dopamine-signaling pathway that
exerts downstream effects through calcium signaling
by hydrolyzing phosphatidylionositol. This binding inter-
action was found to inhibit the catalytic activity of PLCβ
by 50%. Later studies have suggested α-syn also prevents
the degradation of a specific type of PLCβ – PLCβ1, to in
turn promote calcium signaling [61]. Interestingly, A53T
mutations in α-syn that are linked to familial PD are also
associated with weaker binding to PLCβ [60]. Hence, this
could potentially serve as a mechanism by which α-synperturbs downstream effects of PLCβ as a consequence of
reduced activation of lipid signaling pathways.
α-Synuclein exerts a wider influence on lipid metabolism in
the brain
The in vitro findings summarized above are largely
specific for neuronal physiology, which is characteristic of
the bulk of α-syn research. However, the primary
oligodendrocyte pathology exhibited in MSA demands
a broader consideration of the function of this protein
in the brain. A research team headed by E.J. Murphy
of the Ohio State University has published a number of
important studies suggesting a wider role for α-syn in brain
lipid metabolism. This includes a study demonstrating that
astrocytes cultured from α-syn gene-ablated mice have
significantly disrupted uptake of the fatty acids palmitate
and arachidonic acid with increased trafficking to the
neutral lipid pool and decreased trafficking to phospholipids
[62]. Again in whole brains of α-syn−/− mice, uptake
of palmitic acid was reduced by 35% and there was
significantly altered incorporation into a number of
phospholipid classes [63]. It is proposed that these effects
on fatty acid uptake and trafficking are independent of
any function as a FABP on account of the failure to
demonstrate any binding of α-syn to oleic or palmitic
acid using titration microalorimetry [63]. The mechanism
may instead relate to α-syn regulation of acyl-CoA synthase
activity, which mediates incorporation of palmitate into the
acyl-CoA pool from where it is incorporated into individual
phospholipids [63,64].
From the same research team, Ellis and colleagues [65]
found a significant reduction in the linked complex I/III
activity of the electron transport chain in mitochondria
of α-syn−/− mice. This was apparently mediated by reduced
levels and altered fatty acid composition of cardiolipin, an
important component of the mitochondrial membrane
required for assembly and function of the electron
transport chain. Of significance and unlike PD, there
is no significant deficit in mitochondrial respiratory chain
activity in MSA [66]. However, this may still be of particu-
lar relevance to MSA since oxidative stress precipitates
MSA neuropathology, as evidenced by the potentiat-
ing effects of mitochondrial toxin 3-nitroproprionic
acid on clinical deficits and neurodegeneration in
transgenic mouse models of the disease [67,68]. While
speculative, in MSA dysfunction of myelin respiratory
chain activity may be affected due to alterations in myelin
lipid homeostasis.
In summary, α-syn appears to have diverse roles in brain
lipid metabolism, including lipid-mediated signaling
pathways and fatty acid trafficking to key phospholipid
pools integral to the structure and function of biological
membranes. These functions may be integral to an
understanding of the reciprocal influences of lipid
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as discussed below.
Pathophysiology mechanisms of lipids in MSA
Shifts in membrane-associated α-synuclein observed in MSA
brains
The in vitro evidence for the pathogenicity of membrane
bound forms of α-syn has been substantiated by several
studies of human brain tissue fractionates from individuals
affected by MSA and other α-synucleinopathies. Case–
control analyses of α-syn solubility in human brain
tissue have shown increases in sodium dodecyl sulfate
(SDS)-soluble ‘membrane-associated’ α-syn in disease
affected regions of MSA brains with concomitant
decreases or no change in the buffer-soluble cytosolic
fraction [69-74]. These observations lend support to
the hypothesis that a solubility shift from the cytosolic to
membrane compartment may be a fundamental process in
α-syn pathology in α-synucleinopathies. Furthermore, one
detailed comparative study of PD and MSA brain tissue
[74] revealed distinct patterns of α-syn solubility between
the disease groups. Along with the expected wider regional
involvement in MSA, there was also much greater
quantitative accumulation of membrane-associated α-syn
in the MSA substantia nigra compared to PD. The extent
of membrane associated α-syn accumulation also appeared
to positively correlate with neurodegeneration in MSA
(especially in the striatum) but not in PD. Hence,
these disparities highlight that unique pathophysiologies
of α-syn dysfunction are likely to operate in MSA and PD,
which would explain the fundamentally different cellular
focus of pathology in each disease.
Association of COQ2 with pathogenesis of MSA
A recent collaborative study that combined linkage
analysis with whole-genome sequencing of a post-mortem
sample from a member of a multiplex family with a
history of MSA, has provided the first piece of evidence
linking COQ2 to MSA [10]. More specifically, the
common V343A variant in the COQ2 gene was found
to be associated with an increased risk of sporadic MSA in
Japanese populations [10]. The COQ2 gene encodes a
biosynthetic enzyme in the production of coenzyme
Q10 (also known as ubiquinone) [75]. Coenzyme Q10
is a lipid-soluble compound that acts as a powerful
antioxidant and the main electron acceptor in the
electron transport respiratory chain. It is present in
membranes of all cells and tissues, and is vital for the
intracellular transport of electrons from complex I and II
to complex III in the respiratory chain [76]. It is of interest
that the α-syn−/− mice have dysfunction at this site in the
respiratory chain [65]. While generally concentrated
within mitochondria, myelin also possesses the capacity to
undergo oxidative phosphorylation and generate ATP foraxons through functional electron transport chains
within myelin membranes [25], and therefore requires
coenzyme Q10 to perform this function. By measuring
the effects of the V343A variant in lymphoblastoid
lines, the collaborators demonstrated the variant induced
functional impairments in COQ2, which is consistent with
the decreased coenzyme Q10 levels in MSA brains in
comparison to control [10].
Dysfunction and decreased levels of coenzyme Q10
promotes oxidative stress through an inability to remove
free radicals, ultimately facilitating apoptosis-induced cell
death [77,78]. Thus in the context of MSA, dysfunctional
and apoptotic oligodendrocytes as a consequence of
altered coenzyme Q10 function could contribute towards
an inability to form and maintain myelin, which may
impact on the long-term viability of demyelinated axons
(see above). Interestingly, deficiencies of coenzyme
Q10 appear to manifest with some symptomatic features
characteristic of MSA, such as cerebellar ataxia and
atrophy [79,80].
According to Fünfschilling and colleagues [81] however,
the disruption of oxidative phosphorylation in cultured
oligodendrocytes by inhibiting the formation of the
mitochondrial complex IV does not impede the ability
of oligodendrocytes to myelinate axons. Instead, the
authors proposed that oligodendrocytes are capable of
compensatory glycolytic activity upon disruption of
oxidative phosphorylation, as evidenced by a significantly
increased glycolytic rate in affected oligodendrocytes.
Therefore, the role of coenzyme Q10 in MSA is unclear
and will require further in-depth investigation, although
its role in contributing towards oxidative stress remains
plausible (discussed below).
ABCA8 – a novel oligodendrocyte lipid transporter
Besides COQ2, recent investigation of a novel member
of the ATP-binding cassette (ABC) transporter family,
ABCA8, has opened the way to a more detailed
understanding of myelin formation and pathology. ABC
transporters are transmembrane proteins that utilize the
energy of adenosine triphosphate (ATP) hydrolysis to
carry out certain biological processes [82,83]. The A
subfamily of ABC transporters shares a common substrate
specificity for lipid species [84] and several members
have well characterized associations with human disease
including neurodegeneration [85]. ABCA8 has recently
been shown to be differentially expressed in multiple
regions of adult human brains with significantly higher
expression in oligodendrocyte-enriched white matter
regions compared to grey matter cortical regions [86]. The
expression of ABCA1 (the prototype in A subfamily)
was unaltered in white matter regions, suggesting that
ABCA8 may have a unique role in the brain white
matter (Figure 2). Furthermore, in the same study,
Figure 2 Elevated expression of the lipid transporter ABCA8 in
white matter regions of human brain. The expression of ABCA8 and
ABCA1 (prototype in A subfamily) was measured in the superior frontal
grey matter (GM) and white matter (WM) and inferior temporal GM
and WM from six normal adults, comprising of three males and three
females, by quantitative PCR; *p < 0.01 (Student’s t test).
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across the human life-span showed increases correlating
with age-associated myelination [87,88] and in conjunction
with upregulation of the myelinating gene p25α. In
vitro, ABCA8 was able to significantly stimulate both
sphingomyelin synthase 1 expression and sphingomyelin
production in a human oligodendrocyte cell line. Sphingo-
myelin is an important glycosphingolipid component ofthe myelin membrane. In sum these results strongly
suggest that ABCA8 regulates lipid metabolism in
oligodendrocytes and potentially plays a role in myelin
formation and maintenance. It is likely that this ATP
requiring transporter co-locates with respiratory chain
proteins producing ATP within the myelin membrane
to perform these roles.
The influence of ABCA8 on sphingomyelin metabol-
ism may have cellular impacts beyond myelin struc-
tural integrity. Sphingomyelin is enriched in lipid-raft
microdomains where it is thought to be an important
mediator of membrane rigidity and permeability [89]
and of compartmentalization of raft-associated cellular pro-
cesses [90]. Sphingomyelin is also part of an important sig-
naling pathway in which it is cleaved by sphingomyelinase
to form ceramide which serves as a second messenger
for cellular functions including cell cycle progression,
proliferation, differentiation and apoptosis (reviewed in
[91]). Sphingomyelin accumulation with or without
significant sphingomyelinase deficiency are features of
Niemann-Pick disease, of which subtypes A, C and D
manifest with irreversible neurological damage [92].
Bleasel and colleagues [93] have tested the hypothesis
that ABCA8 expression is associated with the disease
process of MSA through involvement in the early
disruption of myelin processing with subsequent impacts
on the function and homeostasis of the key disease
proteins α-syn and p25α. ABCA8 mRNA expression
was significantly increased in MSA brains compared
to controls in disease-affected grey matter (putamen
and cerebellum) and disease-affected white matter
underlying the motor cortex with no significant change in
an unaffected region (visual cortex). ABCA8 and p25α
expression were also positively correlated in disease-affected
regions in both MSA and control tissue. These results
strongly suggest that the upregulation of ABCA8 is
associated at some level with the MSA disease process,
possibly in response to reduced ATP production in myelin
if COQ2 is involved (discussed above). The positive
correlation between ABCA8 and p25α may substantiate a
link between ABCA8 and pre-GCIs disease events in line
with the findings of Song and colleagues [28] outlined
above. The relocalisation of p25α from the myelin sheath
to the cell soma observed in this study was proposed
to be part of a wider initial myelin dysfunction in
MSA, consistent with a concurrent disruption of the
putative myelin lipid transporter ABCA8.
The role of transcriptional upregulation of α-syn and
other GCI proteins in the pathogenesis of MSA has been
a contentious issue. Previous quantitative studies of MSA
post-mortem tissue have failed to demonstrate α-syn
overexpression at the mRNA level [15,94-97]. However
it remain possible that small expression changes in
oligodendrocytes could be masked by secondary neuronal
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studies are necessary. Other commentators have suggested
that negative feedback mechanisms may secondarily
suppress SNCA overexpression in established disease [95].
In an in vitro follow-up to the human tissue analysis cited
above [93], overexpression of ABCA8 in cultured MO3.13
oligodendrocytes caused significant increases in expression
of α-syn and p25α at the mRNA level. While caution
is necessary attributing any causative role to ABCA8
in MSA pathogenesis at this stage, these results lend strong
support to the relevance of myelin lipid dysregulation
to α-syn pathology in oligodendrocytes.
Association of cholesterol (rate-limiting lipid for
myelination) and MSA
Higher serum cholesterol associated with decreased
risk of MSA
In contrast to the numerous investigations of PD cohorts,
only two case–control studies have examined the link
between serum lipids and MSA. In the first study, Lee and
colleagues [98] recruited 142 subjects with probable
MSA and 155 age- and gender- matched controls for
a cross-sectional analysis. The risk of MSA in the lowest
quartile of total cholesterol (TC), low density lipoprotein
(LDL) cholesterol and high density lipoprotein (HDL)
cholesterol was significantly higher compared to the
highest quartile of each. The ORs remained significant for
low TC and HDL when adjusting for age, gender, use of
cholesterol-lowering drugs, and histories of hypertension,
diabetes mellitus, and smoking. The authors considered
potential confounders including relative malnutrition with
increasing severity of disease and use of a feeding tube,
however these factors were not significantly correlated
with lipid profiles. The recent second study of MSA in a
Chinese population has confirmed the conclusion of the
first study [99]. Other evidence linking particular dietary
factors to MSA is conflicting however – meat and poultry
consumption has been found to have both a positive [100]
and negative [13] association to the disease in separate
cross-sectional samples.
Correlation to PD evidence
The suggestion of a link between increased MSA risk and
low serum cholesterol is consistent with some observational
studies of PD, but the literature is marked by conflicting
findings. Two prospective cohort studies have reported an
inverse relationship between serum cholesterol and PD risk.
de Lau and colleagues [101] reported a decreased risk of
PD with increasing total cholesterol and evidence of a
dose response relationship, however the association was
restricted to women. Using self-reported total cholesterol
levels, Simon and colleagues [102] also reported a modest
decrease in relative risk with higher total cholesterol levels.
Retrospective case–control studies have also reported ahigher PD occurrence with lower TC and triglycerides
[103] and with low LDL cholesterol [104]. In conflicting
results, one prospective study [105] found an association
between high total cholesterol at baseline and increased
incidence of PD while another found no association [106].
Similarly, observational studies of dietary fat intake have
reported a mix of conflicting associations: increased risk
with increased total fat (particularly animal fat) [107-109],
decreased risk with increased total fat and poly- and
mono-unsaturated fatty acids (FA) [110]; increased risk
with lower dietary cholesterol [111] and no association
[112,113]. However, in a recent meta-analysis, Gudala
and colleagues [114] revealed that there were no associ-
ation between serum cholesterol and risk of PD, suggest-
ing differences in lipid pathophysiology underlying PD
and MSA.
Relevance of peripheral cholesterol homeostasis to the CNS
The mechanism for an increased risk of MSA with low
levels of serum cholesterol is not obvious. The brain is
the most cholesterol rich organ in the body with more
cholesterol in the white matter due to myelin’s increased
membrane density. Disturbances in cholesterol homeostasis
may disrupt cell membranes where α-syn appears to exert
some of its functions [101,105]. However, the fact remains
that cholesterol-bearing lipoproteins in the peripheral
circulation do not cross the blood brain barrier and
most brain cholesterol is synthesized in situ [115]. On the
contrary, oxidized cholesterol derivatives can easily
diffuse across the blood brain barrier and may pro-
vide a mechanism of interaction between central and
peripheral cholesterol pools. These derivatives include
24S-hydroxycholesterol, which appears to be involved
chiefly in excretion of excess brain-synthesized cholesterol
to the periphery [116] while 27-hydroxycholesterol dem-
onstrates a net flux in the opposite direction where it
concentrates in the white matter [117]. In further support
of this possibility, Bosco and colleagues [118] reported
increased levels of locally generated oxidative cholesterol
metabolites in the cortices of DLB patients compared to
controls, and a pro-aggregating effect of oxysterols on
α-syn in vitro. The potential influence of peripheral
cholesterol dyshomeostasis via 27-hydroxycholesterol
is not implicated in the discussion of these findings.
Thus the interaction of peripheral and CNS cholesterol
homeostasis and its relevance to α-syn pathophysiology
in vivo remain speculative.
Alternatively, coenzyme Q10 has been proposed to be a
neuroprotective factor in PD pathogenesis due to its
antioxidant properties [119,120]. Thus, since serum
cholesterol is the strongest determinant of coenzyme Q10
serum levels [121], this could potentially explain reports
of an inverse relationship between serum lipoprotein
levels and PD risk [110]. Since lower serum cholesterol
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and serum cholesterol determines coenzyme Q10 levels
[121] it could be inferred that altered cholesterol
homeostasis in turn alters the amount of coenzyme
Q10 present. As deficiencies in coenzyme Q10 are known
to induce oxidative stress [77,78], this then poses another
mechanism by which peripheral lipid dyshomeostasis could
contribute to the pathogenesis of MSA. This possibility is
also in accordance with the finding that COQ2 mutations
were more common in MSA patients with predominant
cerebellar involvement [10], as a previous study has shown
the cerebellum in both rats and humans contains the
lowest concentration of coenzyme Q10 in the brain [122].
Hence, it appears the cerebellum may have heightened
vulnerability to the damaging consequences of mutations
in the COQ2 gene.
Conclusions
In conclusion α-syn is a predominantly neuronal protein,
which associates with lipid membranes and plays a role
in synaptic vesicle function and turnover. In addition
α-syn has wider roles in brain lipid metabolism, which
are likely to be important to both neuronal and glial cell
function. The studies summarized above provide a guide
for the interaction of lipid dyshomeostasis, altered membrane
composition and α-syn dysfunction. Oligodendrocytes are
responsible for organising and maintaining the bulk of brain
lipid in the form of the specialised myelin membrane. Myelin
instability, potentially mediated by abnormalities of ABCA8
lipid transporter expression, may be an important precursor
to α-syn pathology in MSA, consistent with the unique
oligodendrocyte focus of the disease. ABC transporters
require ATP and functional mutations in COQ2 affecting
coenzyme Q10 affect respiratory chain production of ATP.
Together these deficits may contribute to the death and
dysfunction of oligodendrocytes in MSA. Future studies
should give due focus to the unique lipid-related processes
underlying MSA pathology in contrast to the neuronal
α-synucleinopathies, especially energy production required
for sphingolipid processing and myelin membrane integrity.
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